Achieve Life Sciences, Inc. (ACHV)
After hours:
| Previous Close | 4.5750 |
| Open | 4.5700 |
| Bid | 4.5800 x 400 |
| Ask | 4.6400 x 400 |
| Day's Range | 4.4900 - 4.6400 |
| 52 Week Range | 3.0300 - 10.3000 |
| Volume | |
| Avg. Volume | 93,958 |
| Market Cap | 157.901M |
| Beta (5Y Monthly) | 1.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT. To access the webcast, please use the followi
- GlobeNewswire
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2024 Conference being held at the Seattle Convention Center April 17-18, 2024. The Achieve corporate presenta
- GlobeNewswire
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial results and provided an update on the cytisinicline development program. Recent Highl
